ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical TrialJune 09, 2015
CLEVELAND, OHIO – June 10, 2015 – ImageIQ, an innovative Imaging Software and Contract Research Organization for preclinical research and clinical trials, announced today that it has been chosen by ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies, to provide its full complement of clinical research imaging support services and technology for ContraVir’s Phase III clincal trial of FV-100, an orally available nucleoside analogue prodrug for the treatment of shingles, an infection caused by the reactivation of varicella zoster virus (VZV), and shingles-associated pain, known as post-herpetic neuralgia (PHN). Specifically, ContraVir will leverage ImageIQ’s EDCIQ™ imaging-enabled electronic data capture (EDC) system, customized specifically to the study’s design and workflow to support the management and compliance of all imaging-related activities. ImageIQ will deploy, manage and support mobile imaging devices for field personnel who will capture images of the zoster rash for each study participant accoss multiple time points. Once acquired, images and data will be automatically uploaded to the EDCIQ by a mobile application for immediate centralized QA and reporting, followed by Dermatologist image evaluation using an EDCIQ integrated image viewer and measurements tools. Lastly, ImageIQ will develop and validate the imaging and image evaluation protocols, as well as provide image acquistion qualification, training, and imaging-related management for all study sites and field personnel participating in the study. ImageIQ is a Cleveland Clinic Innovations company.
ImageIQ will be demonstrating its EDCIQ technology at the DIA 2015 Annual Meeting in Washington, DC, June 14-18, Booth #1227.
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development. In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®). CMX157 is active against HBV and more than 200-fold more potent in vitro versus tenofovir against all major HIV subtypes resistant to current therapies. CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. ContraVir intends to develop CMX157 for HBV and HIV in Phase 2 clinical studies.